HROW Q4 2025: Vivi Revenue Jumps 216% as Sales Force Doubles to Target Market Leadership
Harrow’s Q4 2025 saw all core ophthalmic growth drivers accelerate in tandem, with Vivi’s 216% full-year surge prompting a major sales force expansion and signaling a strategic push for category leadership. Operating leverage improved as revenue scaled faster than costs, and the company now enters 2026 with a diversified, momentum-rich portfolio and a clear roadmap to $250 million quarterly revenue by 2027. Investors should watch for execution on new launches, pipeline catalysts, and the impact of channel and reimbursement shifts on segment growth profiles.
Summary
- Vivi Sales Force Expansion: Management is doubling the Vivi team to capture share in underpenetrated dry eye markets.
- IHESO Retina Pivot: Retina adoption and in-office expansion aim to offset ASC reimbursement headwinds and drive durable growth.
- Pipeline and Launches: New product launches and clinical data readouts are set to reshape Harrow’s revenue mix in 2026 and beyond.
Performance Analysis
Harrow delivered 33% year-over-year revenue growth in Q4, capping a year marked by accelerating adoption across its diversified ophthalmic portfolio. Full-year revenue reached $272 million, up 36%, supported by strong execution in branded and specialty segments. Adjusted EBITDA margin expanded as operating leverage materialized, with costs rising slower than top-line gains even amid stepped-up investment in commercial infrastructure and R&D.
Vivi led the charge, with full-year revenue up 216% and Q4 sales up 14% sequentially, as expanded payer coverage and refill persistence (nine refills per covered patient annually) validated its differentiated profile in the dry eye space. IHESO posted 65% year-over-year growth, driven by retina channel penetration and new in-office use cases expanding the addressable market. Triessence, now reported separately, nearly tripled annual revenue, reflecting early but sustainable traction in ocular inflammation. The specialty and compounded portfolio rebounded after inventory constraints, with normalization expected in Q1 2026.
- Operating Leverage Evident: EBITDA growth outpaced revenue as fixed costs were absorbed across a scaling portfolio.
- Segment Diversification: No single product dominates, with Vivi, IHESO, Triessence, and specialty each contributing materially to the revenue mix.
- Commercial Investment Ramps: SG&A and R&D are set to rise in 2026 as sales teams expand and key clinical programs advance.
Cash generation remained healthy, with $44 million in operating cash flow and a $72.9 million year-end cash balance supporting planned investments and launch activities.
Executive Commentary
"For the first time, all of our core growth drivers accelerated simultaneously. That alignment reinforces our confidence and supports our goal of exceeding $250 million in quarterly revenue by the end of 2027."
Mark Baum, Chief Executive Officer
"This margin expansion demonstrates the operating leverage in our model as revenue scales faster than costs, even as we continue investing in commercialization and R&D."
Andrew Bull, President and Chief Financial Officer
Strategic Positioning
1. Vivi’s Bid for Dry Eye Leadership
Vivi, cyclosporine-based dry eye therapy, is positioned to become the category’s top prescribed agent. Expanded payer coverage and a doubling of the sales force are designed to drive both volume and market share, with management targeting north of 20% share to lead the cyclosporine class. Persistence metrics (nine annual refills per patient) support a durable revenue stream as access widens and commercial intensity increases.
2. Retina and In-Office Expansion for IHESO
IHESO, ophthalmic anesthetic, is transitioning from ASC (ambulatory surgery center) reliance to in-office and retina settings, adding 2.5 million annual procedures to its total addressable market. This pivot is critical as ASC pass-through reimbursement ends in Q2 2026. Clinical data readouts mid-year and a retina-focused packaging launch are expected to further catalyze adoption and price realization.
3. Triessence and Specialty Portfolio Upside
Triessence, injectable steroid for ocular inflammation, is gaining traction as protocol adoption grows in surgical accounts. The sales force is being doubled to deepen penetration, and management expects the product’s momentum to be sustainable due to entrenched physician preferences once adopted. The specialty and compounded portfolio, under new leadership, is also targeted for incremental growth with new coding decisions and study readouts expected to unlock latent value.
4. Pipeline and Launch Execution
G-MELT and BioViz, representing pipeline and biosimilar launches, are expected to reshape the revenue mix by 2027. The G-MELT procedural sedation candidate addresses a large unmet need for opioid- and IV-free anesthesia, with NDA submission targeted for early 2027. BioViz, a Lucentis-referenced biosimilar, will leverage the existing retina sales force with modest market share expectations but high incremental profitability.
Key Considerations
Harrow’s 2025 performance reflects a diversified ophthalmic platform scaling multiple growth drivers in parallel. The company’s strategy hinges on broadening access, maximizing commercial reach, and disciplined investment in both mature and emerging products.
Key Considerations:
- Sales Force Productivity: Success of the Vivi and Triessence expansions depends on rapid onboarding and effective territory management to drive new-to-brand patient capture.
- Channel Inventory Dynamics: Q1 2026 will be impacted by IHESO channel inventory drawdown and seasonally high deductible resets, with a pronounced second-half revenue weighting expected.
- Reimbursement and Pricing Shifts: Loss of ASC pass-through for IHESO requires successful in-office conversion and price improvement initiatives to sustain growth.
- Pipeline Catalysts: Clinical data for IHESO and Triessence, along with G-MELT NDA progress, represent major inflection points for future value realization.
- Compounded to Branded Migration: Transitioning compounded volume to FDA-approved products should enhance margin and revenue durability over time.
Risks
Execution risk looms large, especially with aggressive sales force expansion and multiple product launches in flight. Channel and reimbursement changes, particularly for IHESO, could pressure near-term results if in-office adoption lags. Pipeline milestones are binary events, and delays or negative data could dampen growth expectations. Competitive intensity in dry eye and biosimilars remains high, requiring sustained commercial and clinical differentiation.
Forward Outlook
For Q1 2026, Harrow expects:
- Revenue softness due to channel inventory drawdown for IHESO and seasonal insurance dynamics.
- Minimal IHESO revenue as Q4 inventory is worked through in the channel.
For full-year 2026, management guided to:
- Revenue of $350 million to $365 million, with a back-half weighting.
- Adjusted EBITDA of $80 million to $100 million, majority generated in H2.
Management expects:
- Vivi and Triessence sales force expansions to drive prescription growth as the year progresses.
- IHESO in-office expansion and pricing improvement to offset ASC losses by year-end.
- Biosimilar launches and pipeline data to contribute incremental growth and margin expansion.
Takeaways
Harrow’s Q4 2025 marks a turning point, with synchronized acceleration across all major franchises and a deliberate investment cycle to sustain growth.
- Commercial Execution Key: The doubling of the Vivi and Triessence sales teams underpins management’s confidence in capturing leadership in both dry eye and ocular inflammation.
- Resilient Growth Model: Channel, reimbursement, and inventory headwinds are being actively managed with diversified revenue streams and new market opportunities.
- Pipeline-Driven Upside: G-MELT and biosimilar launches, alongside clinical data milestones, could materially alter the company’s revenue and margin profile by 2027.
Conclusion
Harrow enters 2026 with momentum, a broadened commercial footprint, and a pipeline set to deliver outsized impact over the next two years. While execution risks remain, especially around launch and sales force ramp, the company’s diversified model and visible growth levers provide a credible path to sustained value creation.
Industry Read-Through
Harrow’s performance and strategic moves signal several broader industry trends: The shift from ASC to in-office procedures reflects payer pressure and the need for channel agility in specialty pharma. Aggressive sales force scaling in underpenetrated therapeutic categories highlights the importance of commercial infrastructure in driving prescription volume, especially as payer coverage expands. The migration from compounded to FDA-approved branded products is a margin and compliance lever that other specialty pharma players may look to emulate. Finally, biosimilar launches with modest share targets but high incremental profitability underscore the evolving economics of ophthalmology and specialty biologics markets.